Qingyi Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qingyi Zhu has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Ping Liu
Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, Life Sciences College, Nanjing Normal University, Nanjing 210000, China
4 shared publications Yong Wei
Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
4 shared publications- Luming Shen
Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publications Hongxi Wu
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
2 shared publications- Jianzhong Lin
Jiangsu Taizhou People's Hospital
2 shared publications Jingjing Duan
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
2 shared publications
Latest Publications
- 11 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218727
A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5/DDIT3 pathway to promote docetaxel resistance in prostate cancer
- 11 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218727
A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5/DDIT3 pathway to promote docetaxel resistance in prostate cancer
- Open Access
- 9 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (2) , e46529
Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis: A case report and literature review
Rationale: To investigate the clinical features, management strategies, and prognosis of the rare condition of upper tract urothelial carcinoma (UTUC) with skin metastasis, with emphasis on the efficacy and safety of disitamab vedotin combined with tislelizumab in systemic therapy, we performed a literature search and selection. We searched PubMed, Embase, and Web of Science for English-language publications from January 1, 1990, through December 10, 2024 (last search December 10, 2024). Predefined terms combined “upper tract urothelial carcinoma” or “UTUC” with “skin,” “cutaneous,” “abdominal wall,” or “port-site,” and with “metastasis,” “implantation,” or “seeding.” Inclusion criteria were human case reports or small series with histologically confirmed UTUC and cutaneous involvement. We excluded non-UTUC primaries, noncutaneous metastases, pure reviews without primary cases, duplicate reports, and articles lacking extractable case-level clinical or pathologic data. Two reviewers independently screened records and extracted data (patient and tumor features, site and timing of cutaneous involvement, other metastases, postdiagnosis treatment, and outcomes), resolving discrepancies by consensus. Owing to rarity and heterogeneity, we performed a qualitative descriptive synthesis without meta-analysis. Patient concerns: A patient developed a progressively enlarging cutaneous mass on the abdominal wall at a prior laparoscopic port site following renal cyst surgery. Diagnoses: Biopsy confirmed metastatic poorly differentiated urothelial carcinoma. On April 27, 2023, the patient underwent robot-assisted radical nephrectomy with abdominal wall tumor resection and latissimus dorsi myocutaneous flap transfer. Postoperative pathology revealed high-grade urothelial carcinoma with human epidermal growth factor receptor 2 (+++) expression. Interventions: Gemcitabine/cisplatin was administered initially; however, due to intolerance to cisplatin-based chemotherapy, sequential disitamab vedotin (120 mg every 3 weeks) plus tislelizumab (200 mg every 3 weeks) was initiated on November 23, 2023. Outcomes: At 24-month postoperative follow-up, there was no evidence of local recurrence at the surgical site. Lessons: Cutaneous metastasis in UTUC is rare and portends a poor prognosis. Radical surgery combined with systemic therapy remains the cornerstone of care. In this case, disitamab vedotin plus tislelizumab, used as a postoperative sequential systemic regimen, demonstrated favorable safety and achieved a 24-month recurrence-free interval after discontinuation of gemcitabine/cisplatin due to intolerance, with manageable adverse effects. This combination may represent a potential treatment option for metastatic UTUC, although its efficacy requires validation in larger cohorts.
- 9 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (2) , e46529
Open AccessChemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis: A case report and literature review
Rationale: To investigate the clinical features, management strategies, and prognosis of the rare condition of upper tract urothelial carcinoma (UTUC) with skin metastasis, with emphasis on the efficacy and safety of disitamab vedotin combined with tislelizumab in systemic therapy, we performed a literature search and selection. We searched PubMed, Embase, and Web of Science for English-language publications from January 1, 1990, through December 10, 2024 (last search December 10, 2024). Predefined terms combined “upper tract urothelial carcinoma” or “UTUC” with “skin,” “cutaneous,” “abdominal wall,” or “port-site,” and with “metastasis,” “implantation,” or “seeding.” Inclusion criteria were human case reports or small series with histologically confirmed UTUC and cutaneous involvement. We excluded non-UTUC primaries, noncutaneous metastases, pure reviews without primary cases, duplicate reports, and articles lacking extractable case-level clinical or pathologic data. Two reviewers independently screened records and extracted data (patient and tumor features, site and timing of cutaneous involvement, other metastases, postdiagnosis treatment, and outcomes), resolving discrepancies by consensus. Owing to rarity and heterogeneity, we performed a qualitative descriptive synthesis without meta-analysis. Patient concerns: A patient developed a progressively enlarging cutaneous mass on the abdominal wall at a prior laparoscopic port site following renal cyst surgery. Diagnoses: Biopsy confirmed metastatic poorly differentiated urothelial carcinoma. On April 27, 2023, the patient underwent robot-assisted radical nephrectomy with abdominal wall tumor resection and latissimus dorsi myocutaneous flap transfer. Postoperative pathology revealed high-grade urothelial carcinoma with human epidermal growth factor receptor 2 (+++) expression. Interventions: Gemcitabine/cisplatin was administered initially; however, due to intolerance to cisplatin-based chemotherapy, sequential disitamab vedotin (120 mg every 3 weeks) plus tislelizumab (200 mg every 3 weeks) was initiated on November 23, 2023. Outcomes: At 24-month postoperative follow-up, there was no evidence of local recurrence at the surgical site. Lessons: Cutaneous metastasis in UTUC is rare and portends a poor prognosis. Radical surgery combined with systemic therapy remains the cornerstone of care. In this case, disitamab vedotin plus tislelizumab, used as a postoperative sequential systemic regimen, demonstrated favorable safety and achieved a 24-month recurrence-free interval after discontinuation of gemcitabine/cisplatin due to intolerance, with manageable adverse effects. This combination may represent a potential treatment option for metastatic UTUC, although its efficacy requires validation in larger cohorts.
- Open Access
- 10 June 2025
- Published by Elsevier in Asian Journal of Urology
- Vol. 12 (4) , 512-519
Laparoendoscopic single-site robot-assisted nephroureterectomy: Comparison with the conventional multiport laparoendoscopic technique for upper tract urothelial carcinoma in the retroperitoneal approach
- 10 June 2025
- Published by Elsevier in Asian Journal of Urology
- Vol. 12 (4) , 512-519
Open AccessLaparoendoscopic single-site robot-assisted nephroureterectomy: Comparison with the conventional multiport laparoendoscopic technique for upper tract urothelial carcinoma in the retroperitoneal approach
- Open Access
- 7 January 2025
- Published by Wiley in FASEB BioAdvances
- Vol. 7 (2) , e1488
NCAPD3‐mediated AKT activation regulates prostate cancer progression
Despite therapeutic improvements in prostate cancer treatment, the recurrence and mortality rates are still high, and the underlying mechanisms still need further study. Non‐SMC Condensin II Complex Subunit D3 (NCAPD3) is a subunit of condensin II complex, mainly involved in the mitotic chromosome condensation of cells. This study aimed to figure out the detailed mechanisms by which NCAPD3 contributed to prostate cancer development. Clinical samples and cell lines were used to measure the expression of genes by quantitative real‐time RT‐PCR (qRT‐PCR), Western‐blot assay (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR) and dual‐luciferase reporter assays were examined to explore the interplays between molecules. CCK8, transwell, and wound‐healing assays were applied to perform cell proliferation and migration. A subcutaneous tumor xenograft model was constructed by injecting DU145‐Lv‐NCAPD3 cells and control cells into male BALB/c nude mice to confirm the result derived from in vitro assay. NCAPD3 increased STAT3 expression and phosphorylation in PCa cells, thereby enhancing STAT3 transcriptional activity to improve the levels of JAK2 and EZH2. This led to an increase in phosphorylation of AKT at Thr 308 and Ser 473 through JAK2/PI3K and EZH2/NSD2/mTORC2 pathways, respectively. Moreover, there was a positive mutual activation between STAT3 and JAK2, further enhanced by NCAPD3 to promote PCa progression. NCAPD3, as an oncogene, promoted PCa progression by phosphorylating and activating AKT, which suggests a novel functional pathway of NCAPD3 in promoting PCa progression.
- 7 January 2025
- Published by Wiley in FASEB BioAdvances
- Vol. 7 (2) , e1488
Open AccessNCAPD3‐mediated AKT activation regulates prostate cancer progression
Despite therapeutic improvements in prostate cancer treatment, the recurrence and mortality rates are still high, and the underlying mechanisms still need further study. Non‐SMC Condensin II Complex Subunit D3 (NCAPD3) is a subunit of condensin II complex, mainly involved in the mitotic chromosome condensation of cells. This study aimed to figure out the detailed mechanisms by which NCAPD3 contributed to prostate cancer development. Clinical samples and cell lines were used to measure the expression of genes by quantitative real‐time RT‐PCR (qRT‐PCR), Western‐blot assay (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Chromatin immunoprecipitation quantitative PCR (ChIP‐qPCR) and dual‐luciferase reporter assays were examined to explore the interplays between molecules. CCK8, transwell, and wound‐healing assays were applied to perform cell proliferation and migration. A subcutaneous tumor xenograft model was constructed by injecting DU145‐Lv‐NCAPD3 cells and control cells into male BALB/c nude mice to confirm the result derived from in vitro assay. NCAPD3 increased STAT3 expression and phosphorylation in PCa cells, thereby enhancing STAT3 transcriptional activity to improve the levels of JAK2 and EZH2. This led to an increase in phosphorylation of AKT at Thr 308 and Ser 473 through JAK2/PI3K and EZH2/NSD2/mTORC2 pathways, respectively. Moreover, there was a positive mutual activation between STAT3 and JAK2, further enhanced by NCAPD3 to promote PCa progression. NCAPD3, as an oncogene, promoted PCa progression by phosphorylating and activating AKT, which suggests a novel functional pathway of NCAPD3 in promoting PCa progression.
- Open Access
- 2 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (31) , e39176
A comparative cross-platform analysis of cuproptosis-related genes in human nonobstructive azoospermia: An observational study
This study aimed to identify novel biomarkers associated with cuproptosis in human nonobstructive azoospermia (NOA). We obtained 4 NOA microarray datasets (GSE145467, GSE9210, GSE108886, and GSE45885) from the NCBI Gene Expression Omnibus database and merged them into training set. Another NOA dataset (GSE45887) was used as validation set. Differentially expressed cuproptosis-related genes were identified from training set. Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes pathway analyses were conducted. Least absolute shrinkage and selection operator regression and support vector machine-recursive feature elimination were used to identify hub cuproptosis-related genes. We calculated the expression of the hub cuproptosis-related genes in both validation set and patients with NOA. Gene set variation analysis was used to explore their potential biological functions. The risk prediction model was built by logistic regression analysis and was evaluated in the validation set. Finally, we constructed a competing endogenous RNA network. The training set included 29 patents in the control group and 92 in the NOA group, and 10 cuproptosis-related differentially expressed genes were identified. Subsequently, we screened 6 hub cuproptosis-related genes (DBT, GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1) by least absolute shrinkage and selection operator regression and support vector machine-recursive feature elimination. GCSH, NFE2L2, NLRP3, and SLC31A1 expressed higher in NOA group than in control group (P < .05) in the validation set (4 patients in control and 16 in NOA groups), while the expression levels of GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1 were higher in NOA group than in control group (P < .05) in our patients (3 patients in control and 4 in NOA groups). The model based on the 6-gene signature showed superior performance with an AUC value of 0.970 in training set, while 1.0 in validation set. Gene set variation analysis revealed a higher enrichment score of “homologous recombination” in the high expression groups of the 6 hub genes. Finally, we constructed a competing endogenous RNA network and found hsa-miR-335-3p and hsa-miR-1-3p were the most frequently related to the 6 hub genes. DBT, GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1 may serve as predictors of cuproptosis and play important roles in the NOA pathogenesis.
- 2 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (31) , e39176
Open AccessA comparative cross-platform analysis of cuproptosis-related genes in human nonobstructive azoospermia: An observational study
This study aimed to identify novel biomarkers associated with cuproptosis in human nonobstructive azoospermia (NOA). We obtained 4 NOA microarray datasets (GSE145467, GSE9210, GSE108886, and GSE45885) from the NCBI Gene Expression Omnibus database and merged them into training set. Another NOA dataset (GSE45887) was used as validation set. Differentially expressed cuproptosis-related genes were identified from training set. Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes pathway analyses were conducted. Least absolute shrinkage and selection operator regression and support vector machine-recursive feature elimination were used to identify hub cuproptosis-related genes. We calculated the expression of the hub cuproptosis-related genes in both validation set and patients with NOA. Gene set variation analysis was used to explore their potential biological functions. The risk prediction model was built by logistic regression analysis and was evaluated in the validation set. Finally, we constructed a competing endogenous RNA network. The training set included 29 patents in the control group and 92 in the NOA group, and 10 cuproptosis-related differentially expressed genes were identified. Subsequently, we screened 6 hub cuproptosis-related genes (DBT, GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1) by least absolute shrinkage and selection operator regression and support vector machine-recursive feature elimination. GCSH, NFE2L2, NLRP3, and SLC31A1 expressed higher in NOA group than in control group (P < .05) in the validation set (4 patients in control and 16 in NOA groups), while the expression levels of GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1 were higher in NOA group than in control group (P < .05) in our patients (3 patients in control and 4 in NOA groups). The model based on the 6-gene signature showed superior performance with an AUC value of 0.970 in training set, while 1.0 in validation set. Gene set variation analysis revealed a higher enrichment score of “homologous recombination” in the high expression groups of the 6 hub genes. Finally, we constructed a competing endogenous RNA network and found hsa-miR-335-3p and hsa-miR-1-3p were the most frequently related to the 6 hub genes. DBT, GCSH, NFE2L2, NLRP3, PDHA1, and SLC31A1 may serve as predictors of cuproptosis and play important roles in the NOA pathogenesis.
- Open Access
- 13 March 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-6
Robot-assisted single-port retroperitoneal partial nephrectomy with a novel purpose-built single-port robotic system with deformable surgical instruments
Objective: To investigate the safety and feasibility of using a novel purpose-built single-port robotic system (the SHURUI Robotic Surgical System) with deformable surgical instruments to perform retroperitoneal single-port partial nephrectomy. Materials and methods: A prospective study was conducted to recruit patients with a single renal tumor no more than 4 cm. Robot-assisted single-port partial nephrectomy was performed by using the novel purpose-built single-port robotic system with deformable surgical instruments. Patients’ demographics, tumor characteristics, and perioperative parameters were recorded and analyzed. Results: Sixteen patients were recruited to the study. The median tumor size was 2.0 cm (IQR: 1.2–2.4 cm). The median R.E.N.A.L score was 6 (IQR: 4–4.5). In 3 cases, pure single-port surgery was carried out, and all the assistance was through the robotic port. Median docking time was 15.5 min (IQR: 14.25–22.25 min). Median operating time was 148.5 min (IQR: 178–238.5 min). Median console time was 107 min (IQR: 92.75–149.75 min). Median warm ischemic time was 26.5 min (IQR: 24.5–30 min). Median blood loss was 17.5 ml (IQR: 10–50 ml). Conclusions: Retroperitoneal partial nephrectomy can be safely performed with this novel purpose-built single-port robotic system (SHURUI) with deformable surgical instruments. Further studies are needed to fully evaluate the role of this new platform.
- 13 March 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-6
Open AccessRobot-assisted single-port retroperitoneal partial nephrectomy with a novel purpose-built single-port robotic system with deformable surgical instruments
Objective: To investigate the safety and feasibility of using a novel purpose-built single-port robotic system (the SHURUI Robotic Surgical System) with deformable surgical instruments to perform retroperitoneal single-port partial nephrectomy. Materials and methods: A prospective study was conducted to recruit patients with a single renal tumor no more than 4 cm. Robot-assisted single-port partial nephrectomy was performed by using the novel purpose-built single-port robotic system with deformable surgical instruments. Patients’ demographics, tumor characteristics, and perioperative parameters were recorded and analyzed. Results: Sixteen patients were recruited to the study. The median tumor size was 2.0 cm (IQR: 1.2–2.4 cm). The median R.E.N.A.L score was 6 (IQR: 4–4.5). In 3 cases, pure single-port surgery was carried out, and all the assistance was through the robotic port. Median docking time was 15.5 min (IQR: 14.25–22.25 min). Median operating time was 148.5 min (IQR: 178–238.5 min). Median console time was 107 min (IQR: 92.75–149.75 min). Median warm ischemic time was 26.5 min (IQR: 24.5–30 min). Median blood loss was 17.5 ml (IQR: 10–50 ml). Conclusions: Retroperitoneal partial nephrectomy can be safely performed with this novel purpose-built single-port robotic system (SHURUI) with deformable surgical instruments. Further studies are needed to fully evaluate the role of this new platform.
- Open Access
- 18 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1207061
Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
Background: Immunogenic cell death (ICD) is considered a particular cell death modality of regulated cell death (RCD) and plays a significant role in various cancers. The connection between kidney renal clear cell carcinoma (KIRC) and ICD remains to be thoroughly explored.Methods: We conducted a variety of bioinformatics analyses using R software, including cluster analysis, prognostic analysis, enrichment analysis and immune infiltration analysis. In addition, we performed Quantitative Real-time PCR to evaluate RNA levels of specific ICD genes. The proliferation was measured through Cell Counting Kit-8 (CCK-8) assay and colony-formation assay in RCC cell lines. Results: We determined two ICD subtypes through consensus clustering analysis. The two subtypes showed significantly different clinical outcomes, genomic alterations and tumor immune microenvironment. Moreover, we constructed the ICD prognostic signature based on TF, FOXP3, LY96, SLC7A11, HSP90AA1, UCN, IFNB1 and TLR3 and calculated the risk score for each patient. Kaplan-Meier survival analysis and ROC curve demonstrated that patients in the high-risk group had significantly poorer prognosis compared with the low-risk group. We then validated the signature through external cohort and further evaluated the relation between the signature and clinical features, tumor immune microenvironment and immunotherapy response. Given its critical role in ICD, we conducted further analysis on LY96. Our results indicated that downregulation of LY96 inhibited the proliferation ability of RCC cells.Conclusions: Our research revealed the underlying function of ICD in KIRC and screened out a potential biomarker, which provided a novel insight into individualized immunotherapy in KIRC.
- 18 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1207061
Open AccessIdentification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
Background: Immunogenic cell death (ICD) is considered a particular cell death modality of regulated cell death (RCD) and plays a significant role in various cancers. The connection between kidney renal clear cell carcinoma (KIRC) and ICD remains to be thoroughly explored.Methods: We conducted a variety of bioinformatics analyses using R software, including cluster analysis, prognostic analysis, enrichment analysis and immune infiltration analysis. In addition, we performed Quantitative Real-time PCR to evaluate RNA levels of specific ICD genes. The proliferation was measured through Cell Counting Kit-8 (CCK-8) assay and colony-formation assay in RCC cell lines. Results: We determined two ICD subtypes through consensus clustering analysis. The two subtypes showed significantly different clinical outcomes, genomic alterations and tumor immune microenvironment. Moreover, we constructed the ICD prognostic signature based on TF, FOXP3, LY96, SLC7A11, HSP90AA1, UCN, IFNB1 and TLR3 and calculated the risk score for each patient. Kaplan-Meier survival analysis and ROC curve demonstrated that patients in the high-risk group had significantly poorer prognosis compared with the low-risk group. We then validated the signature through external cohort and further evaluated the relation between the signature and clinical features, tumor immune microenvironment and immunotherapy response. Given its critical role in ICD, we conducted further analysis on LY96. Our results indicated that downregulation of LY96 inhibited the proliferation ability of RCC cells.Conclusions: Our research revealed the underlying function of ICD in KIRC and screened out a potential biomarker, which provided a novel insight into individualized immunotherapy in KIRC.
- 24 January 2022
- Published by Elsevier in Cellular Signalling
- Vol. 92, 110265
NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1
- 24 January 2022
- Published by Elsevier in Cellular Signalling
- Vol. 92, 110265
NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1)
Ferroptosis Induction Improves the Sensitivity of Docetaxel in Prostate Cancer
Docetaxel resistance seriously affects its clinical application in prostate cancer (PCa). Ferroptosis is a type of iron‐dependent cell death driven by lipid peroxidation. It has been recently found that ferroptosis influences various biological processes. However, the potential role of ferroptosis in docetaxel chemotherapy for PCa is still elusive. In this study, we aimed to explore whether altering the level of ferroptosis can affect docetaxel sensitivity in PCa. The results indicated that docetaxel promoted ferroptotic cell death in several PCa cells, and ferroptosis inducers, erastin, and RSL3 markedly increased the cytotoxic effect of docetaxel. Furthermore, our results showed that ferroptosis resistance was closely associated with docetaxel insensitivity in PCa‐resistant cells. Erastin or RSL3 rendered resistant PCa cells susceptible to docetaxel, with elevated levels of lipid ROS and decreased protein expression of GPX4 and SLC7A11. Moreover, treatment with erastin and RSL3 led to significant suppression of resistant tumors, and the combination of RSL3 with docetaxel significantly halted tumor growth in vivo when compared with either drug. Taken together, our findings indicate that ferroptosis is involved in docetaxel resistance, and its inducers are promising therapeutic strategies for advanced PCa.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1)
Open AccessFerroptosis Induction Improves the Sensitivity of Docetaxel in Prostate Cancer
Docetaxel resistance seriously affects its clinical application in prostate cancer (PCa). Ferroptosis is a type of iron‐dependent cell death driven by lipid peroxidation. It has been recently found that ferroptosis influences various biological processes. However, the potential role of ferroptosis in docetaxel chemotherapy for PCa is still elusive. In this study, we aimed to explore whether altering the level of ferroptosis can affect docetaxel sensitivity in PCa. The results indicated that docetaxel promoted ferroptotic cell death in several PCa cells, and ferroptosis inducers, erastin, and RSL3 markedly increased the cytotoxic effect of docetaxel. Furthermore, our results showed that ferroptosis resistance was closely associated with docetaxel insensitivity in PCa‐resistant cells. Erastin or RSL3 rendered resistant PCa cells susceptible to docetaxel, with elevated levels of lipid ROS and decreased protein expression of GPX4 and SLC7A11. Moreover, treatment with erastin and RSL3 led to significant suppression of resistant tumors, and the combination of RSL3 with docetaxel significantly halted tumor growth in vivo when compared with either drug. Taken together, our findings indicate that ferroptosis is involved in docetaxel resistance, and its inducers are promising therapeutic strategies for advanced PCa.
- 30 September 2021
- Published by Wiley in The Prostate
- Vol. 82 (1) , 26-40
Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer
Background: Androgen receptor (AR) is an essential transcriptional factor that contributes to the development and progression of prostate cancer (PCa). NCAPD3 is a component of the condensin II complex and plays a critical role in cell mitosis by regulating chromosome condensation; however, the relationship between NCAPD3 and AR remains unknown.Methods: Transcriptome sequencing assay is carried out to analyze the expression of the NCAP family in clinic samples. Chromatin immunoprecipitation (ChIP) sequencing, ChIP assay, and dual‐luciferase assay are used to identify the androgen‐responsive element in NCAPD3 enhancer. Immunohistochemistry, quantitative reverse transcription‐polymerase chain reaction, and western‐blot assay are employed to check the expression of genes in PCa tissues and in PCa cells. Confocal immunofluorescence microscopy analysis is used for identifying the regulation of AR on NCAPD3‐mediated chromosome condensation. Colony formation, cell cycle assay, wound healing assay, and transwell experiments are used to explore the regulation of AR on the functions of NCAPD3. In vivo experiment is employed to identify in vitro experimental results.Results: NCAPD3 is an androgen/AR axis‐targeted gene and is involved in AR‐induced PCa cell proliferation, migration, and invasion in vitro and in vivo. Androgen treatment and AR overexpression increase the expression of NCAPD3 in PCa cell lines. The canonical exist in the enhancer region of NCAPD3. Androgen/AR axis regulates NCAPD3‐invovled chromosome condensation during cell mitosis.Conclusions: Our report demonstrated that NCAPD3 is an androgen‐responsive gene and upregulated by androgen/AR axis and involved in AR‐promoted progression of PCa, suggesting a potential role of NCAPD3 in the PCa development.
- 30 September 2021
- Published by Wiley in The Prostate
- Vol. 82 (1) , 26-40
Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer
Background: Androgen receptor (AR) is an essential transcriptional factor that contributes to the development and progression of prostate cancer (PCa). NCAPD3 is a component of the condensin II complex and plays a critical role in cell mitosis by regulating chromosome condensation; however, the relationship between NCAPD3 and AR remains unknown.Methods: Transcriptome sequencing assay is carried out to analyze the expression of the NCAP family in clinic samples. Chromatin immunoprecipitation (ChIP) sequencing, ChIP assay, and dual‐luciferase assay are used to identify the androgen‐responsive element in NCAPD3 enhancer. Immunohistochemistry, quantitative reverse transcription‐polymerase chain reaction, and western‐blot assay are employed to check the expression of genes in PCa tissues and in PCa cells. Confocal immunofluorescence microscopy analysis is used for identifying the regulation of AR on NCAPD3‐mediated chromosome condensation. Colony formation, cell cycle assay, wound healing assay, and transwell experiments are used to explore the regulation of AR on the functions of NCAPD3. In vivo experiment is employed to identify in vitro experimental results.Results: NCAPD3 is an androgen/AR axis‐targeted gene and is involved in AR‐induced PCa cell proliferation, migration, and invasion in vitro and in vivo. Androgen treatment and AR overexpression increase the expression of NCAPD3 in PCa cell lines. The canonical exist in the enhancer region of NCAPD3. Androgen/AR axis regulates NCAPD3‐invovled chromosome condensation during cell mitosis.Conclusions: Our report demonstrated that NCAPD3 is an androgen‐responsive gene and upregulated by androgen/AR axis and involved in AR‐promoted progression of PCa, suggesting a potential role of NCAPD3 in the PCa development.